CD4 and Opportunistic infection: Furthermore, lower CD4+-T-cells are known to be a risk factor for the development of herpes zoster virus reactivation in MM patients receiving bortezomib, as well as for opportunistic infections in patients with MM receiving conventional therapy (6, 28).